Skip to main content

Cell and gene therapy startup ElevateBio raises $170 million

While economic conditions and the ongoing global coronavirus pandemic may not make for the best atmosphere for raising funding, some companies are still announcing round closures with significant money committed. Cambridge-based ElevateBio, for instance, revealed a $170 million Series B funding on Monday, with participation from new investors The Invus Group, Surveyor Capital, EDBI, and Vertex Ventures, along with existing investors F2 Ventures, MPM Capital, EcoR1 Capital, Redmile Group and Samsara BioCapital.

ElevateBio, which was officially launched to the public less than a year ago, specializes in development of new types of cellular and genetic therapies, and operates by the creation of new companies under its portfolio each dedicated to the development and manufacturing of a specific type of therapeutic approach. This funding brings the total raised by ElevateBio to over $300 million, on top of a $150 million Series A round that the company announced last year, led by Swiss investment bank UBS’ Oncology Impact Fund.

The biotech company has ramped up quickly, nearing completion of a 140,000 square foot facilitating in Massachusetts to focus on R&D. It also launched a company called AlloVir that’s working on T-cell immunotherapy for combating viruses that specifically arise stem cell transplantations, and is already in the later stages of clinical trials. Finally, it launched another company called HighPassBio, which is also aimed at helping treat stem cell-related diseases using T-cell therapies, in this case specifically around the potential relapse of leukaemia following a transplant.

As you might expect, ElevateBio is also turning the attention of some of its efforts towards research focused on mitigating the impact of COVID-19; specifically, its AlloVir subsidiary has expanding an existing research agreement in place with the Baylor College of Medicine to work on developing a type of T-cell therapy that can help protect patients with conditions that compromise their immune systems and put them at increased risk for COVID-19.



from Startups – TechCrunch https://ift.tt/39vuzW5
Labels:

Comments

Post a Comment

Popular posts from this blog

Axeleo Capital raises $51 million fund

Axeleo Capital has raised a $51 million fund (€45 million). Axeleo first started with an accelerator focused on enterprise startups. The firm is now all grown up with an acceleration program and a full-fledged VC fund. The accelerator is now called Axeleo Scale , while the fund is called Axeleo Capital . And it’s important to mention both parts of the business as they work hand in hand. Axeleo picks up around 10 startups per year and help them reach the Series A stage. If they’re doing well over the 12 to 18 months of the program, Axeleo funds those startups using its VC fund. Limited partners behind the company’s first fund include Bpifrance through the French Tech Accélération program, the Auvergne-Rhône-Alpes region, Vinci Energies, Crédit Agricole, BNP Paribas, Caisse d’Épargne Rhône-Alpes as well as various business angels and family offices. The firm is also partnering with Hi Inov, the holding company of the Dentressangle family. Axeleo will take care of the early stage in...
Post a Comment
Read more

TikTok’s rivals in India struggle to cash in on its ban

For years, India has served as the largest open battleground for Silicon Valley and Chinese firms searching for their next billion users. With more than 400 million WhatsApp users , India is already the largest market for the Facebook-owned service. The social juggernaut’s big blue app also reaches more than 300 million users in the country. Google is estimated to reach just as many users in India, with YouTube closely rivaling WhatsApp for the most popular smartphone app in the country. Several major giants from China, like Alibaba and Tencent (which a decade ago shut doors for most foreign firms), also count India as their largest overseas market. At its peak, Alibaba’s UC Web gave Google’s Chrome a run for its money. And then there is TikTok, which also identified India as its biggest market outside of China . Though the aggressive arrival of foreign firms in India helped accelerate the growth of the local ecosystem, their capital and expertise also created a level of competit...
Post a Comment
Read more